Clinical Trial

Effects of Inhaled Treprostinil on Exercise Performance in Exercise Induced Pulmonary Hypertension

Not Yet Recruiting Early Phase 1
View on ClinicalTrials.gov →
Summary
This study aims to investigate therapies for exercise induced pulmonary hypertension (EiPH). This is a condition that effects the blood vessels in the lungs and causes shortness of breath with activity. Currently, there are very limited treatment options for this condition. Inhaled treprostinil, also known as Tyvaso, is a medication used to treat other forms of lung disease and is safe and well tolerated. This study will measure the ability of Tyvaso to improve symptoms related to EiPH and improve performance on exercise testing.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-08-07.
Trial Details
NCT Number NCT07116681
Lead Sponsor University of California, San Diego
Collaborators: United Therapeutics
Conditions Pulmonary Hypertension
Enrollment 8 participants
Start Date 2025-10-01
Primary Completion 2027-07-01 (estimated)
Study Completion 2027-07-01 (estimated)
Updated on ClinicalTrials.gov 2025-08-24